E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10031289 |
E.1.2 | Term | Osteoporosis, unspecified |
E.1.2 | System Organ Class | 100000004859 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the predictive value of markers of bone turnover on bone loss 12 months after stopping alendronate therapy. Primary endpoint: To investigate to what extent changes in carboxy- terminal collagen crosslinks (CTX) 3 and 6 months after stopping alendronate treatment predict changes in total hip BMD after 1 year. |
|
E.2.2 | Secondary objectives of the trial |
Secondary endpoints: - To investigate to what extent baseline CTX when stopping alendronate treatment predicts changes in total hip BMD after 1 year. - To investigate to what extent changes in procollagen type I N- terminal propeptide (PINP) 3 and 6 months af-ter stopping alendronate treatment predict changes in total hip BMD after 1 year. - To investigate to what extent changes in the ratio CTX/PINP 3/6 months after stopping alendronate treatment predict changes in total hip BMD after 1 year. - The proportion of the study population in which bone turnover increases to above premenopausal/young adult reference levels after 3, 6, and 12 months. - The proportion of the study population who loses BMD beyond least significant change in lumbar spine and total hip. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria: • Postmenopausal women (postmenopausal for at least two years) • Men above 50 years • Treatment for at least five years with alendronat • BMD T-score total hip > -2.5 • BMD T-score lumbar spine (L1-L4) > -4 |
|
E.4 | Principal exclusion criteria |
Exclusion criteria: • Any low-energy fracture within the previous 5 years during alendronat treatment (not including fingers, toes, or skull) • Low-energy vertebral fracture at any time • Low-energy hip fracture at any time • Ongoing treatment with glucocorticoids • Metabolic bone disease • Hormone replacement therapy • Cancer • Other conditions affecting bone metabolism |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint: To investigate to what extent changes in carboxy-terminal collagen crosslinks (CTX) 3 and 6 months after stopping alendronate treatment predict changes in total hip BMD after 1 year. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
To investigate to what extent changes in carboxy-terminal collagen crosslinks (CTX) 3 and 6 months after stopping alendronate treatment predict changes in total hip BMD after 1 year. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints: - To investigate to what extent baseline CTX when stopping alendronate treatment predicts changes in total hip BMD after 1 year. - To investigate to what extent changes in procollagen type I N- terminal propeptide (PINP) 3 and 6 months af-ter stopping alendronate treatment predict changes in total hip BMD after 1 year. - To investigate to what extent changes in the ratio CTX/PINP 3/6 months after stopping alendronate treatment predict changes in total hip BMD after 1 year. - The proportion of the study population in which bone turnover increases to above premenopausal/young adult reference levels after 3, 6, and 12 months. - The proportion of the study population who loses BMD beyond least significant change in lumbar spine and total hip. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- To investigate to what extent baseline CTX when stopping alendronate treatment predicts changes in total hip BMD after 1 year. - To investigate to what extent changes in PINP 3 and 6 months af-ter stopping alendronate treatment predict changes in total hip BMD after 1 year. - To investigate to what extent changes in the ratio CTX/PINP 3/6 months after stopping alendronate treatment predict changes in total hip BMD after 1 year. - The proportion of the study population in which bone turnover increases to above premenopausal/young adult reference levels after 3, 6, and 12 months. - The proportion of the study population who loses BMD beyond least significant change in lumbar spine and total hip. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject undergoing the trial. The study will be terminated for the individual participant if the investigator suspects that the participant will be at risk of serious, life-threatening events if he or she continues as part of the study. If the DXA scans show a rapidly declining BMD > 8% during the first 6 months, the study will be terminated for this participant and treatment for osteoporosis will be re-initiated. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |